Overview


According to FutureWise analysis the market for antibiotics active pharmaceutical ingredient (api) in 2023 is US$ 8.65 billion, and is expected to reach US$ 11.41 billion by 2031 at a CAGR of 3.5%.

The Active Pharmaceutical Ingredient (API) is the bioactive substance within a drug product (such as a tablet, capsule, cream, or injectable) that induces the desired therapeutic effects. Antibiotic active pharmaceutical ingredients (AAPIs) represent biochemical drugs traditionally manufactured through the age-old process of microbial fermentation; a practice human have employed for decades.

The production of antibiotics APIs traditionally involves a process known as microbial fermentation. This age-old technique harnesses the metabolic activities of microorganisms like bacteria, fungi, or molds to produce the desired antibiotic compounds. Over the decades, this fermentation process has been refined and optimized, leading to the efficient and large-scale production of antibiotics APIs. Once produced, antibiotics APIs undergo extensive testing and quality control measures to ensure their safety, purity, and efficacy. This involves a series of rigorous analytical and microbiological tests to verify the identity, potency, and absence of impurities or contaminants. These quality control procedures guarantee that the antibiotic's APIs meet stringent regulatory standards before being formulated into finished drugs. Antibiotic APIs play a pivotal role in the pharmaceutical industry, serving as the foundation for developing and manufacturing various antibiotic medications. These drugs are vital in treating common ailments like urinary tract infections and more severe conditions such as pneumonia and sepsis.

FutureWise Market Research has published a report that provides an insightful analysis of Antibiotics Active Pharmaceutical Ingredient (API) Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Antibiotics Active Pharmaceutical Ingredient (API) Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Sandoz International GmbH.
  • Centrient Pharmaceuticals
  • CordenPharma International
  • ACS DOBFAR SPA
  • Nanjing Dorra Pharmaceutical Technology Co. Ltd.
  • DAEWOONG PHARMACEUTICAL CO. LTD.
  • Parabolic Drugs Ltd.
  • Penam Laboratories Ltd.
  • ASIATIC DRUGS
  • PHARMACEUTICALS PVT. LTD.
  • Fresenius Kabi
  • The United Laboratories International Holdings Limited
  • Aurobindo Pharma Limited
  • Unimark Remedies Ltd.
  • Savior Lifetec
  • Shenzhen Haibin Pharmaceutical Co., Ltd.
  • Sterile India Pvt. Ltd.
  • Zhejiang Jiuzhou Pharmaceutical Co. Ltd.
  • Kyongbo Pharm

(Note: The list of the major players will be updated with the latest market scenario and trends)

By API Type

  • Penicillin Antibiotics
    • Ampicillin
    • Amoxicillin
    • Dicloxacillin
    • Penicillin G Sodium
    • Benzathine
    • Procaine
  • Cephalosporins
    • Cefotaxime
    • Ceftriaxone
    • Cefuroxime
    • Cefalotin
  • Carbapenem Antibiotics
    • Meropenem
    • Imipenem
    • Ertapenem

By End User

  • Pharmaceutical Companies
  • Contract Manufacturing Organizations (CMOs)
  • Contract Development and Manufacturing Organizations (CDMOs)

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Antibiotics Active Pharmaceutical Ingredient (API) Market By API Type, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Antibiotics Active Pharmaceutical Ingredient (API) Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antibiotics Active Pharmaceutical Ingredient (API) Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Antibiotics Active Pharmaceutical Ingredient (API) Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Antibiotics Active Pharmaceutical Ingredient (API) Market, By API Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Penicillin Antibiotics
         1.1. Ampicillin
         1.2. Amoxicillin
         1.3. Dicloxacillin
         1.4. Penicillin G Sodium
         1.5. Benzathine
         1.6. Procaine
        2. Cephalosporins
         2.1. Cefotaxime
         2.2. Ceftriaxone
         2.3. Cefuroxime
         2.4. Cefalotin
        3. Carbapenem Antibiotics
         3.1. Meropenem
         3.2. Imipenem
         3.3. Ertapenem

  • 8.   Antibiotics Active Pharmaceutical Ingredient (API) Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pharmaceutical Companies
        2. Contract Manufacturing Organizations (CMOs)
        3. Contract Development and Manufacturing Organizations (CDMOs)

  • 9.   North America Antibiotics Active Pharmaceutical Ingredient (API) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Antibiotics Active Pharmaceutical Ingredient (API) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Antibiotics Active Pharmaceutical Ingredient (API) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Antibiotics Active Pharmaceutical Ingredient (API) Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Sandoz International GmbH.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Centrient Pharmaceuticals
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. CordenPharma International
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. ACS DOBFAR SPA
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Nanjing Dorra Pharmaceutical Technology Co. Ltd.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. DAEWOONG PHARMACEUTICAL CO. LTD.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Parabolic Drugs Ltd.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Penam Laboratories Ltd.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. ASIATIC DRUGS & PHARMACEUTICALS PVT. LTD.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Fresenius Kabi
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. The United Laboratories International Holdings Limited
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Aurobindo Pharma Limited
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Unimark Remedies Ltd.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Savior Lifetec
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
           15. Shenzhen Haibin Pharmaceutical Co., Ltd.
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Sterile India Pvt. Ltd.
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Zhejiang Jiuzhou Pharmaceutical Co. Ltd.
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Kyongbo Pharm
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients